Author Interview: Professor Axel Finckh and Associate Professor Bente Glintborg, August 2026

Discussing PsA: Advances in Psoriatic Arthritis Management and Treatment Safety

Join Professor Laura Coates and Professor Philip Mease as they discuss a recent publication examining minimal clinically important improvement thresholds in PsA. This month’s conversation explores recent advances in PsA and immune-mediated inflammatory disease therapies.

Author Interview: Professor Axel Finckh and Associate Professor Bente Glintborg, August 2026

Join Professor Peter Nash from the Griffith University in Brisbane; Professor Axel Finckh, from the Division of Rheumatology, Geneva University Hospitals, Geneva, Switzerland; and Bente Glintborg, an Associate Professor from the Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark as they discuss his recent paper ‘Influence of the shared epitope on the effectiveness of biologic antirheumatic agents in European patients with rheumatoid arthritis’.

Discussing RA: Advanced therapy outcomes in RA

Join Professor Iain McInnes and Doctor Philip Mease for the latest episode of Discussing RA on The Immune-Mediated Inflammatory Disease Forum. In this episode, they examine key findings from studies by Fleischmann et al. and Nozaki et al. discussing the long-term effectiveness and safety of advanced targeted therapies for RA.

Author Interview: Professor Laura Coates, July 2026

Join Professor Peter Nash from the Griffith University in Brisbane, and Laura Coates, Professor at the University of Oxford’s Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, as they discuss a recent paper ‘Ixekizumab with tirzepatide achieved greater disease control than ixekizumab alone in adults with psoriatic arthritis and overweight or obesity: Results from a randomized clinical trial’.

Discussing axSpA: Long-term safety and efficacy of bimekizumab and ixekizumab in r-axSpA

Join Dr Sofia Ramiro and Professor Atul Deodhar as they discuss the top publications in the world of axSpA. This month, the conversation covered the long-term safety and efficacy of bimekizumab and ixekizumab in r-axSpA.